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Abstract 
 
Background 
We tested whether inflammation is associated with worsening depressive symptoms in type 2 
diabetes and examined whether sex moderated this association.  
 
Research Design and Methods 
In a prospective cohort study of people with newly diagnosed type 2 diabetes, we measured 
depressive symptoms over 2-year follow-up using the Patient Health Questionnaire-9 (PHQ-
9). The independent variable was a composite inflammation burden score at diagnosis of 
diabetes, derived from high-sensitivity C-reactive protein, white cell count, interleukin (IL)-
1β, IL-1 receptor antagonist, monocyte chemotactic protein-1 and vascular endothelial 
growth factor concentrations. General linear models assessed i) the association between 
overall inflammation burden and estimated marginal mean PHQ-9 score (natural log (ln)-
transformed) at 2 years; and ii) the interaction between elevated (above-median) 
inflammation burden and sex on ln-PHQ-9 score. Models were adjusted for age, ethnicity, 
body mass index, blood pressure, cholesterol, HbA1c, antidepressants, anti-inflammatory 
medications and baseline ln-PHQ-9 score. 
 
Results 
Of 1174 people with complete inflammation data, mean age was 56.7 (11.0) years, 46.1% 
were of non-white ethnicity and 44.1% female. After full adjustment, inflammation burden 
was not associated with worsening ln-PHQ-9 score (p=0.65). However, there was a 
significant interaction between sex and inflammation on 2-year ln-PHQ-9 score (β=0.32, 
p=0.005), showing that the difference by inflammation burden in females was 0.32 larger 
than in males. In post-hoc comparisons, ln-PHQ-9 score was higher in females than males 
with elevated inflammation (p=0.003) but not with low inflammation burden (p=0.34). 
 
Conclusion 
In type 2 diabetes, female sex confers specific vulnerability to the effects of inflammation on 
depressive symptoms.   
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Introduction 
 
Depressive symptoms are reported by 10-30% of people with type 2 diabetes – twice as often 
as in the general population – and are associated with 1.5-3-fold increased frequency of 
diabetes complications and premature mortality.1–3 In a psychological model of the 
association, depressive symptoms could be formulated as negative cognitions and emotions to 
the burden of a chronic disease, in turn leading to poor diabetes outcomes through reduced 
diabetes self-care.4 This model, however, provides limited opportunities to understand 
disease mechanisms and improve outcomes. For example, in cohort studies, depressive 
symptoms are not always associated with worsening in glycaemic control over time,5 
suggesting that depression does not consistently lead to worsening diabetes self-care. In 
neuroimaging research, the brain changes typical of depression – such as hippocampal 
atrophy – mirror those seen in type 2 diabetes.6,7 Moreover, the link is bidirectional: whereas 
type 2 diabetes is associated with increased risk of incident depressive symptoms, the 
converse association is even stronger.8  
 
A unifying explanation for these observations is that depressive symptoms and type 2 
diabetes are not distinct conditions, but rather may be linked by shared disease mechanisms, 
such as elevated inflammation.9 In support, pro-inflammatory cytokines and elevated acute 
phase proteins are associated with onset of depression and type 2 diabetes, respectively,10,11 
whilst some anti-inflammatory therapies have demonstrated benefit in the two conditions 
separately.12,13 To date, research testing inflammation as a link between depression and type 2 
diabetes has been scarce. In cross-sectional studies in people with type 2 diabetes, those with 
comorbid depressive symptoms had higher concentrations of acute phase proteins and 
cytokines, even after adjustment for confounders such as body mass index (BMI), smoking, 
and age.14–16 However, no prospective cohort study has tested the association between 
inflammation and the course of depressive symptoms over time in people with type 2 
diabetes, such that potential causality cannot yet be inferred. 
 
Like depressive symptoms, female sex is associated with increased risk of cardiovascular 
complications in people with type 2 diabetes, even accounting for sex differences in other 
major cardiovascular risk factors.17 Depressive symptoms are also nearly twice as prevalent 
in females than males with established type 2 diabetes.18 In depression research, female sex 
appears to increase vulnerability to the effects of inflammation on the brain,19 and anti-
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inflammatory diabetes treatments may improve depressive symptoms more significantly in 
females.20 Collectively, this suggests that inflammation could lead predominantly to 
depressive symptoms in females with type 2 diabetes and further could provide an 
explanation for the poor overall prognosis of female diabetes. 
 
Using an incident type 2 diabetes cohort, we therefore aimed to test the hypotheses that 
elevated inflammation is associated with worsening depressive symptoms in people with type 
2 diabetes and secondly that this association is stronger in females than in males.  
 
Research Design and Methods 
 
Setting and study design: The South London Diabetes (SOUL-D) study is a population-based 
prospective cohort of people with newly diagnosed type 2 diabetes recruited within six 
months of diagnosis and followed over 2 years.21 The study was set in the inner-city boroughs 
of Lambeth, Southwark, and Lewisham in South London, which collectively have 
approximately 0.75 million residents from diverse ethnic- and socioeconomic backgrounds. 
All General Practice (GP) surgeries in these boroughs were invited to participate. Local 
protocols for diagnosis of type 2 diabetes followed World Health Organisation criteria.22 
Ethical approval was granted by the King’s College Hospital Research Ethics Committee 
(reference 08/H0808/1) and by Lambeth, Southwark, and Lewisham Primary Care Trusts 
(reference RDLSLB 410). All participants gave written informed consent, including for 
access to their medical records. Details of inclusion criteria and recruitment timetable have 
been published.21 
 
Outcomes: The outcome at 2-year follow-up was depressive symptoms, as measured by total 
Patient Health Questionnaire-9 (PHQ-9) score. Due to positive skew, we natural log-
transformed PHQ-9 scores. As discussed previously, the PHQ-9 is a 9-item questionnaire 
based on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) 
diagnostic criteria for clinical depression, which has been validated for use in people with 
type 2 diabetes.23 Missing PHQ-9 data (where <20% of responses were missing) were 
imputed using case mean substitution, discussed in detail previously.5  
 
Independent variable: The independent variable was a composite measure of inflammation 
burden based on six markers of inflammation: high-sensitivity C-reactive protein (hs-CRP), 
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interleukin-1β (IL-1β), IL-1 receptor antagonist (IL-1RA), monocyte chemotactic protein-1 
(MCP-1), vascular endothelial growth factor (VEGF), and white blood cell count (WBC). As 
well as measuring a range of inflammatory pathways – including acute phase-, cytokine- and 
chemokine responses – these markers were selected because of their positive individual 
associations with depressive symptoms in the baseline SOUL-D cohort.14 As in previous 
research,24 a composite inflammation burden score was calculated by transforming each 
measure into a z-distribution, whose mean is 0 and standard deviation is 1, before averaging 
the individual biomarker z-scores. This approach minimises multiple testing and reduces the 
influence of the biological variability of each measure. Serum hs-CRP was measured using an 
Advia 2400 analyzer (Siemens Diagnostics, Frimley, UK) with detection limit 0.1 mg/L; 
WBC was measured using an Advia 2120 analyzer (Siemens Diagnostics); and IL-1β, IL-
1RA, VEGF and MCP-1 were measured from serum samples centrifuged from venous blood 
samples taken after an overnight fast, stored between −40 and −80°C using cytokine-array 
biochip kits (Randox, Belfast, UK) and analyzed using the Randox Evidence Investigator; the 
inter- and intra-assay coefficients of variation for all analytes measured using these kits are 
<15 and <10%, respectively.  
 
Confounders: We considered the following potential confounders a priori: age, ethnicity 
(white versus non-white), BMI, blood pressure, smoking status, HbA1c (measured by affinity 
chromatography [Primus Ultra2, Kansas City, USA]), serum total cholesterol (measured 
using Siemens Advia 2400 Analyzer, detection limit 0.01 mmol/L), prescription of any anti-
inflammatory medications (systemic steroids, nonsteroidal anti-inflammatory drugs 
[NSAIDs]) and antidepressant medications. 
 
Statistical analyses 
 
Baseline analysis: Data were analysed using IBM SPSS version 25.0. We compared the 
following baseline characteristics of the cohort stratified by low- or elevated inflammation 
burden at baseline: sociodemographic variables (age, self-report ethnicity 
[African/Caribbean, white, South Asian/other]); baseline biomedical variables (smoking 
status, total cholesterol, BMI, HbA1c, inflammatory markers, anti-inflammatory medications, 
antidepressant medications, blood pressure, inflammatory marker concentrations); and 
baseline PHQ-9 score. For continuous variables, we used Student’s t-test for normally 
distributed data and the Mann-Whitney U test for skewed data, and for categorical variables 
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we used chi-square tests. Results were presented as mean (SD) or median (interquartile 
range) for skewed data, unless otherwise stated. Compared to those included in the analysis, 
we assessed the characteristics of people missing inflammation data at baseline. 
 
Prospective association between inflammation burden and depressive symptoms: the 
prospective analysis comprised unadjusted- and adjusted general linear models in which the 
outcome was 2-year PHQ-9 score (natural log-transformed). We firstly tested whether 
elevated inflammation burden (total inflammation z-score) was associated with elevated 
PHQ-9 score at follow-up in the whole cohort after adjustment for baseline PHQ-9 score. We 
next adjusted the model for the range of potential confounders. Associations were reported 
using the standardised beta coefficient and its associated p-value. 
 
Interaction between inflammation and sex on course of depressive symptoms: We next used 
general linear models to test the interaction between sex and inflammation burden on 2-year 
PHQ-9 score. We firstly measured the beta-coefficient of the interaction, which presents the 
difference in PHQ-9 score between low- and elevated inflammation status in females 
compared to males. We next interrogated the directionality of any interaction using the 
estimated marginal mean (EMM) difference in PHQ-9 score at follow-up by comparing the 
differences in PHQ-9 score between females and males within the low- and elevated 
inflammation groups. Estimated marginal means are presented at mean values for each 
covariate (rather than resetting them to 0, as in linear regression models), which provides a 
clinically relevant measure of the association between inflammation and depression course in 
a typical patient (in this case a patient with average baseline depression score and average 
score or average proportion for other covariates and categorical variables respectively). The 
unadjusted interaction model comprised the outcome 2-year PHQ-9 score (natural log-
transformed) and the independent variables of sex, inflammation status, sex*inflammation 
status, and baseline PHQ-9 score. We next adjusted the model for the full range of 
confounders. Interactions were also displayed graphically.  
 
Sensitivity analyses: To account for missing data, we performed multiple imputation analyses 
with 20 multiply imputed datasets. Incomplete variables were imputed under fully 
conditional specification, using iterative Markov chain Monte Carlo (MCMC) estimation 
method. All variables were included in the imputation process, including interactions 
between PHQ-9 score (ln-transformed) and sex at both time points. The parameters of 
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interest were estimated in each imputed dataset separately and combined using Rubin’s 
rules.25 Finally, to account for participants who may have had elevated inflammation due 
to an acute infection, we conducted a further sensitivity analysis excluding those with hs-
CRP concentration >10mg/L at baseline.26 
 
Results 
 
Ninety-six out of 136 (70.6%) GP surgeries agreed to participate. From their diabetes 
registers, a target population of 3008 newly-diagnosed type 2 diabetes patients were 
identified, of whom 2406 people were potentially eligible and invited to participate, and of 
whom 1735 people consented. Of these, 1174 (67.7%) provided complete data on all 6 
inflammatory markers and were included in the current analysis. The mean age of this subset 
was 56.7 (11.0) years, 44.1% were female and 46.1% of non-white ethnicity. 
 
Compared with those included in the analysis, those with missing inflammation data were 
younger (55.0 [11.0] versus 56.7 [11.0] years, p=0.003), had slightly higher BMI (32.5 [6.7] 
versus 31.8 [6.4] kg/m2, p=0.032), slightly lower total cholesterol (4.50 [1.1] versus 4.62 
[1.1] mmol/L, p=0.044), higher baseline depressive symptoms (3 [1-7] versus 2 [0-6], 
p=0.009), were more often of non-white ethnicity (65.0% versus 48.7%, p<0.001), smokers at 
baseline (24.5% versus 19.0%, p=0.011), and less likely to be prescribed NSAIDs/steroids 
(23.2% versus 30.0%, p=0.003), or antidepressants at baseline (1.2% versus 7.3%, p<0.001). 
However, there were no differences in proportion of female sex (p=0.14), baseline HbA1c 
(p=0.21), BMI (p=0.99), systolic blood pressure (p=0.47) or diastolic blood pressure (p=0.89) 
(test statistics not shown).  
 
Baseline comparisons: Compared to those with low inflammation burden, people with 
elevated inflammation burden were older, had higher BMI, higher total cholesterol, higher 
hs-CRP, higher baseline PHQ-9 score, were more often of African/Caribbean ethnicity than 
white, smokers at baseline, and prescribed antidepressant medication. There were no 
differences by inflammation burden in sex, South Asian ethnicity, blood pressure, glycaemic 
control and prescription of anti-inflammatory medication (Table 1). 
 
[Insert Table 1 here] 
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Follow-up: A total of 803 (68.4%) of people provided both inflammation and 2-year PHQ-9 
data. Compared to those followed up, people with missing data were younger (55.1 [11.6] 
years versus 57.4 [10.7] years, p=0.001), more likely to be female (49.1% versus 41.8%, 
p=0.021), of non-white ethnicity (52.8% versus 43.0%, p=0.002), to have low inflammation 
burden (56.1% versus 46.6%, p=0.002), had higher baseline HbA1c (7.14 [1.5] versus 6.90 
[1.4], p=0.006), and higher baseline diastolic blood pressure (84.0 [11.2] versus 82.6 [10.4], 
p=0.04). However, there were no differences by attrition in proportion of smokers (p=0.64), 
prescription of NSAIDs/steroids at baseline (p=0.34), prescription of antidepressants at 
baseline (p=0.73), baseline BMI (p=0.13), baseline systolic blood pressure (p=0.55), baseline 
total cholesterol (p=0.98) and baseline total PHQ-9 score (p=0.84) (test statistics not shown).  
 
Prospective association between inflammation burden and course of depressive symptoms: 
Before or after full adjustment, there was no association between inflammation burden at 
baseline and higher PHQ-9 score at 2 years in the whole cohort (Table 2). 
 
[Insert Table 2 here] 
 
Unadjusted interaction between inflammation burden and sex on course of depressive 
symptoms: In the unadjusted general linear model, there was a significant interaction between 
female sex and elevated inflammation burden on change in PHQ-9 score (β =0.36, p=0.001), 
meaning that the difference between low- and elevated inflammation status was 0.36 larger in 
females compared to males (Table 2). A post hoc analysis of the interactions revealed no 
differences in depressive symptoms between males and females with low inflammation 
burden (EMM difference = 0.07, p=0.37), whilst depressive symptoms were significantly 
higher in females than males in the subgroup with elevated inflammation burden (EMM 
difference = 0.29, p<0.001) (Table 3, Figure 1a).  
 
[Insert Table 3 and Figure 1 here]  
 
Adjusted interaction between inflammation burden and sex on depressive symptoms: After 
adjustment for the full range of confounders, including baseline depressive symptoms, the 
interaction remained significant (β=0.32, p=0.005): the difference between low- and elevated 
inflammation burden in females was 0.32 larger than in males (Table 2). Post hoc pairwise 
comparisons again showed that there was no significant difference between males and 
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females in the low inflammation group (EMM difference = 0.08, p=0.34), whereas females 
had higher depressive symptoms than males in the elevated inflammation group (EMM 
difference = 0.23, p=0.003), conditioned on average values of covariates (Table 3, Figure 1b).  
 
Sensitivity analyses: Using multiple imputation for missing data did not alter the conclusions: 
the unadjusted interaction (β = 0.36, p<0.001) and fully adjusted interaction (β = 0.31, 
p<0.001) between female sex and elevated inflammation remained strongly significant. 
Supplemental Table 1 shows the full breakdown of unadjusted- and adjusted interactions after 
multiple imputation. Exclusion of the 147 people with baseline hs-CRP >10mg/L – 
potentially indicating acute infection – likewise did not alter the conclusions: the fully 
adjusted interaction remained significant (β = 0.31, p=0.009) and females had higher 
depressive symptoms than males in subgroup with elevated inflammation (EMM difference = 
0.24 p=0.007).  
 
[Insert Supplemental Table 1 here] 
 
Discussion 
 
In a prospective cohort study of people with newly diagnosed type 2 diabetes recruited from 
primary care, elevated inflammation at diagnosis of type 2 diabetes – as estimated using a 
composite measure of acute phase, cytokine and chemokine markers – was not associated 
with worsening depressive symptoms over 2 years. However, elevated inflammation burden 
was associated with greater worsening depressive symptoms in females compared to males. 
These findings remained robust to adjustment for a range of pro-inflammatory and anti-
inflammatory confounders, including BMI and smoking status.  
 
Comparison with previous literature: Depressive symptoms are commonly reported in people 
with type 2 diabetes and are associated with poor biomedical outcomes.1,2 In addition to 
psychological and behavioural factors, there is increasing evidence that biological 
mechanisms may provide a link between depressive symptoms and type 2 diabetes. In 
particular, previous studies have demonstrated a cross-sectional association between elevated 
inflammation and depressive symptoms in people with type 2 diabetes,14,15 although no 
cohort study has tested this prospectively. Our study therefore marks a clear advance in the 
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literature by demonstrating that inflammation is associated with preferential worsening in 
depressive symptoms in females compared to males with type 2 diabetes. 
 
Although depressive symptoms are nearly twice as prevalent in females with type 2 diabetes 
compared to males,18 the reasons for this predominance are poorly understood. A possible 
explanation is that females are more likely to report depressive symptoms than males, for 
example due to different social processes influencing presentation of psychological distress 
for the different sexes. However, this is not supported by the similar reporting of depressive 
symptoms between males and females with low burden of inflammation in our study. 
Likewise, adjustment for increased BMI – another possible reason for female vulnerability to 
depression27 – did not attenuate our findings.  
 
Echoing prospective findings from the general population,28,29 our results suggest that worse 
depressive symptoms in females with type 2 diabetes could result from elevated 
inflammation. This is likely to occur through dialogue with dysfunction of the hypothalamic-
pituitary-adrenal (HPA) axis. Specifically, activation of the HPA axis by stress should 
normally lead to an increase in glucocorticoid sensitivity, enabling cortisol to inhibit- and 
thus regulate inflammatory responses. Whereas males demonstrate this response consistently, 
stress appears to exert the opposite effect in females, leading to decreased glucocorticoid 
sensitivity and exaggerated inflammatory responses.30 Notably, females in our sample were 
typically of postmenopausal age, by which time HPA axis dysfunction has become most 
pronounced, probably due to loss of modulation by gonadal steroids.31 The presence of a 
dysfunctional HPA axis thereby exposes females to exaggerated effects on inflammation, 
leading to increased risk of cardiovascular disease in the periphery and potentially an 
increased risk of depression centrally.32,33 Central effects may occur through pro-
inflammatory cytokines activating the enzyme indoleamine 2,3-dioxygenease, which diverts 
tryptophan metabolism from serotonin towards neurotoxic metabolites in the brain.33 
 
Interpretation: Our findings suggest that depressive symptoms and female sex – both poor 
prognostic factors in type 2 diabetes respectively – are biologically linked by inflammation. 
The result is an ‘inflammatory depression’ that predominantly affects females, runs a 
persistent course and is poorly explained by lifestyle factors such as smoking and obesity. 
Both female sex and inflammation are strongly associated with cardiovascular risk in type 2 
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diabetes,17,32 and notably the typical hs-CRP concentration for the elevated inflammation 
group in our study was in the range for high cardiovascular risk.26 As such, the inflammatory 
depression of female type 2 diabetes could be an important and potentially modifiable 
biomarker of future cardiovascular disease and mortality, which requires testing over longer-
term follow-up. 
 
Therapeutically, the strong association between female sex and inflammation suggests a need 
to ‘gender’ therapy towards reducing the burden of inflammation in females. For example, in 
managing depression, elevated innate inflammation is associated with poor response to the 
usual first-line antidepressants: selective serotonin reuptake inhibitors (SSRIs).34 In females 
with depressive symptoms, clinicians may therefore consider proactive switching to 
antidepressants that have greater anti-inflammatory properties, such as tricyclic 
antidepressants.34 Likewise, within the repertoire of current diabetes treatments, females with 
type 2 diabetes could be treated earlier with therapies known to have greater anti-
inflammatory properties. For example, incretin-based therapies and thiazolidenediones have 
potent effects on inflammation,35,36 and could even be a novel treatment for depression by 
modifying inflammation.20  
   
As well as repositioning of anti-inflammatory diabetes treatments, our results support trials of 
anti-inflammatory agents for depressive symptoms in type 2 diabetes, which have not yet 
been performed. In the general population, anti-inflammatory- and HPA-axis modifying 
therapies have demonstrated inconsistency in improving depressive symptoms,12,37 and our 
findings suggest that benefit would be maximised by specifically recruiting females to such 
clinical trials. Future experimental medicine studies are needed to profile the dynamic 
immune responses conferring vulnerability to female depressive symptoms in type 2 diabetes, 
thereby providing clearer targets for interventional studies. A better understanding of the 
bidirectional interplay between the HPA axis and inflammation is required, including 
predisposing factors to HPA axis dysfunction, such as changes in gonadal hormones. Finally, 
lifecourse epidemiological research is needed to delineate the temporal relationship between 
inflammation, depression and type 2 diabetes, as well as possible upstream aetiologies such 
as stressful life events. 
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Strengths and limitations: our study is strengthened by its unique multi-ethnic and 
socioeconomically diverse cohort, which is representative of the global type 2 diabetes 
population. By recruiting all patients within 6 months of diagnosis of type 2 diabetes, 
confounding effects of diabetes complications on inflammation and depression were 
minimised. A composite measure of inflammation that included acute phase, cytokine and 
chemokine responses provided a broad yet rigorous test of inflammation. Our data were 
limited by 32% missing values for inflammation burden at baseline, although there were no 
sex differences between those missing data and those included. Although a similar attrition 
rate over 2 years is a further limitation of our study, maximising follow-up is particularly 
challenging in an urban population with high rates of social deprivation, multimorbidity, 
geographical mobility, and a primary care setting in which several GP surgeries closed during 
the study. Furthermore, multiple imputation of missing data resulted in no significant changes 
to the study findings. We did not assess for periodontitis, which could be an important cause 
of inflammation, depression and type 2 diabetes.38,39 We measured depressive symptoms 
continuously using a validated self-report questionnaire, which will likely over-identify 
depressive symptoms compared to a diagnostic interview. However, there is strong evidence 
that subthreshold depressive symptoms are prognostically important in people with 
diabetes.40 Finally, longer follow-up is needed to confirm the persistence of inflammatory 
depression in females, as well as associated biomedical sequelae. 
 
Summary 
In the early stages of type 2 diabetes, inflammation shows no overall association with 
worsening in depressive symptoms over 2-year follow-up. However, inflammation 
demonstrates a preferential association with worsening depressive symptoms in females 
compared to males, which is not explained by potential confounders such as obesity. Future 
studies should test whether inflammation is a modifiable target for reducing the gender gap in 
psychological- and biomedical outcomes in people with type 2 diabetes. 
 
Figure captions 
Figure 1: General linear model testing the interaction between sex and inflammation burden 
on the 2-year course of depressive symptoms in the SOUL-D cohort: a) adjusted only for 
baseline depressive symptoms; b) adjusted for baseline depressive symptoms and the full 
range of confounders. 
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Table 1: Baseline characteristics of the South London Diabetes cohort stratified by inflammation burden at baseline 
Variable Category Total cohorta Elevated 
inflammation 
burdena (n=592) 
Low inflammation 
burdena (n=582) 
p-
valueb 
Sociodemographic variables      
Age, years (SD)  56.7 (11.0) 57.6 (10.9) 55.7 (11.0) 0.003 
Sex (%) Male 656 (55.9) 323 (54.6) 333 (57.2) - 
 Female 518 (44.1) 269 (45.4) 249 (42.8) 0.36 
Ethnicity (%) White  633 (54.0) 394 (66.6) 239 (41.1) - 
      African/Caribbean 417 (35.5) 124 (20.9) 293 (50.3) <0.001c 
      South Asian/other 124 (10.6) 74 (12.5) 50 (8.6) 0.59 c 
Baseline vascular risk factors      
Smoker status (%) Smoker  216 (18.9) 152 (26.3) 64 (11.4) - 
 Non-smoker 924 (81.1) 427 (73.7) 497 (88.6) <0.001 
Mean BMI, kg/m2 (SD)  31.8 (6.4) 32.6 (6.8) 30.9 (5.8) <0.001 
Mean systolic BP, mmHg (SD)  136.1 (17.4) 136.3 (17.5) 136.0 (17.3) 0.78 
Mean diastolic BP, mmHg (SD)  83.0 (10.5) 83.1 (10.6) 82.8 (10.4) 0.61 
Mean HbA1c, % (SD)  6.98 (1.4) 7.02 (1.4) 6.91 (1.4) 0.35 
Mean HbA1c, mmol/mol (SD)  52.8 (10.6) 53.2 (10.6) 52.0 (10.5) 0.35 
Mean total cholesterol, mmol/L 
(SD) 
 4.62 (1.1) 4.70 (1.1) 4.53 (1.0) 0.007 
Baseline inflammatory 
variables 
     
Prescribed NSAIDs/opioids (%) Yes 348 (30.0) 187 (31.9) 161 (28.0) - 
 No 814 (70.0) 400 (68.1) 414 (72.0) 0.15 
Median hs-CRP [IQR]  2.7 [1.1-6.3] 4.6 [1.9-9.0] 1.6 [0.8-3.9] <0.001 
Median IL-1B [IQR]  1.02 [0.73-1.87] 1.16 [0.79-2.64] 0.91 [0.69-1.54] <0.001 
Median IL-1RA [IQR]  437.0 [290.0-695.8] 620.2 [399.4-916.0] 323.8 [223.1-473.4] <0.001 
Median MCP-1 [IQR]  102.3 [59.6-152.2] 138.7 [92.3-189.2] 72.3 [49.9-109.9] <0.001 
Median VEGF [IQR]  76.0 [45.6-118.1] 114.4 [82.1-163.7] 48.9 [33.1-71.7] <0.001 
Median WBC [IQR]  7.6 [6.4-9.0] 8.6 [7.4-10.1] 6.7 [5.7-7.7] <0.001 
Baseline psychological 
variables 
     
Median PHQ-9 score [IQR]  2 [0-6] 3 [1-7] 2 [0-6] <0.001 
Prescribed antidepressants (%) Yes 84 (7.2) 53 (8.9) 31 (5.3) - 
 No 1089 (92.8) 538 (91.1) 551 (94.7) 0.016 
a) Inflammation burden comprises baseline concentrations of white cell count, interleukin-β, interleukin-1 receptor antagonist, high-
sensitivity C-reactive protein, monocyte chemotactic protein-1 and vascular endothelial growth factor. Each concentration is z-
transformed and all 6 measures are averaged to calculate an overall score. This is split by the median value to define elevated- and low 
inflammation burden. b) Parametric continuous data are presented as mean (SD) and compared using Student’s t-test; non-parametric 
continuous data are presented as median [interquartile range] and compared using Mann-Whitney U test; categorical variables 
presented as frequency (%) and compared using chi-square tests. c) Compared to white ethnicity. Key: BMI, body mass index; BP, 
blood pressure; CRP, high-sensitivity C-reactive protein; NSAIDs, non-steroidal anti-inflammatory drugs; PHQ-9, patient health 
questionnaire-9; SD; standard deviation. 
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Table 2: Multivariate analysis testing the associations between inflammation burden and sex on 2-year depressive 
symptoms in the SOUL-D cohort 
Independent variables    
Model 1: inflammation as 
independent variable  
 Adjusted for baseline PHQ-9 
score only 
Fully adjusteda 
Overall inflammation burden 
(continuous) 
β (95% CI), p-value 0.05 (-0.03 to 0.14), p=0.23 0.02 (-0.07 to 0.11), p=0.65 
Inflammation burden (binary) 
(1=elevated, 0=low) 
β (95% CI), p-value 0.09 (-0.02 to 0.19),p=0.11 0.06 (-0.05 to 0.18), p=0.30 
    
Model 2: inflammation, sex and 
their interaction as independent 
variables  
   
Inflammation burden (1=elevated, 
0=low) 
β (95% CI), p-value -0.06 (-0.20 to 0.08), p=0.37 -0.07 (-0.22 to 0.08), p=0.35 
Sex (1=female, 0=male) β (95% CI), p-value -0.07 (-0.23 to 0.09) p=0.37 -0.08 (-0.25 to 0.09), p=0.34 
Interaction (female sex*elevated 
inflammation burden) 
β (95% CI), p-value 0.36 (0.15 to 0.57), p=0.001 0.32 (0.10 to 0.53), p=0.005 
 Total number in model N=797 N=706 
Multivariable general linear models with outcome 2-year Patient Health Questionnaire-9 (PHQ-9) score (natural log-transformed). 
Reference groups are low inflammation burden, male sex, and low inflammation*male sex. a) Adjusted for baseline PHQ-9 score 
(log-transformed), age, non-white ethnicity, body mass index, baseline systolic blood pressure, baseline smoking status, baseline 
serum cholesterol, baseline HbA1c, prescription of anti-inflammatory medication and prescription of antidepressant medication. 
Key: CI, confidence interval 
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Table 3: General linear models testing the interactions between sex and inflammation burden on 2-year depressive 
symptoms in the SOUL-D cohort 
i) Pairwise comparisons between males and females within low- and elevated inflammation groups: adjusted for baseline 
depressive symptoms onlya 
Inflammation 
burden (I) Sex (J) Sex 
Mean 
Difference (I-J) Std. Error Sig. 
95% CI Lower 
Bound 
95% CI Upper 
Bound 
Low Male Female -0.07 0.08 0.37 -0.23 0.09 
Elevated Male Female -0.29 0.07 <0.001 -0.43 -0.14 
ii) Pairwise comparisons between males and females within low- and elevated inflammation groups: fully adjustedb 
Inflammation 
burden (I) Sex (J) Sex 
Mean 
Difference (I-J) Std. Error Sig. 
95% CI Lower 
Bound 
95% CI Upper 
Bound 
Low Male Female 0.08 0.09 0.34 -0.09 0.25 
Elevated Male Female -0.23 0.08 0.003 -0.39 -0.08 
Outcome is estimated marginal mean Patient Health Questionnaire-9 (PHQ-9) score (natural log-transformed) at 2 years. a) 
Adjusted only for baseline PHQ-9 score (natural log-transformed). b) Adjusted for baseline PHQ-9 score (natural log-
transformed), age, non-white ethnicity, body mass index, baseline systolic blood pressure, baseline smoking status, baseline serum 
cholesterol, baseline HbA1c, prescription of anti-inflammatory medication and prescription of antidepressant medication. Key: CI, 
confidence interval. 
 
